Abstracts Archive - Page 595 of 2425 - ACR Meeting Abstracts

Abstract Number: 0643 • ACR Convergence 2021
Tailored BP Connect Protocol with Implementation Support for Rheumatology Clinic Staff Exceeds Non-tailored Protocol at Improving Primary Care Referrals for Blood Pressure Follow-up
David Gazeley¹, Monica Messina², Edmond Ramly², Ann Rosenthal¹, Laurie Lapp², Laura Stewart³ and Christie Bartels², ¹Medical College of Wisconsin, Milwaukee, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI, ³Froedtert & Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Many rheumatic diseases increase risk of cardiovascular disease, yet an important modifiable cardiovascular risk factor, high blood pressure (BP), often remains unaddressed during rheumatology…
Abstract Number: 0642 • ACR Convergence 2021
Prevalence and Risk Factors for Cardio-metabolic Abnormalities in Patients with Inflammatory Arthritis Attending Cardio-rheumatology Primary Prevention Clinics
Lihi Eder¹, Shadi Akhtari², Dana Jerome¹, Jacob Udell¹, Patrick Lawler¹, Paula Harvey³ and Bindee Kuriya⁴, ¹University of Toronto, Toronto, ON, Canada, ²Women's College Hospital, University of Toronto, North York, ON, Canada, ³Women's College Hospital, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Cardio-metabolic abnormalities are common in patients with inflammatory arthritis (IA) but tend to be under-recognized and under-treated. We aimed to compare the prevalence and…
Abstract Number: 0637 • ACR Convergence 2021
Assessing the Rates of Cervical Cancer Screening in Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Tara Skorupa¹, Sonia Khatter², Alana Freifeld¹ and Elena Weinstein³, ¹University of Colorado, Denver, CO, ²University of Colorado, Aurora, CO, ³University of Colorado, Englewood, CO
Background/Purpose: Prior studies have described increased incidence of cervical dysplasia and cervical cancer in women with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), suggesting…
Abstract Number: 0648 • ACR Convergence 2021
Improving Post-Rituximab Hypogammaglobulinemia Risk Assessments: A Fellows’ Quality Improvement Initiative
Beth Rutstein¹, Melissa Argraves², Atiye Bilgic Dagci², Sarah Bayefsky², Julia Rood², Julie Chase³, Jay Mehta², Melissa Lerman², Cory Stingl⁴ and Jon Burnham², ¹Children's Hospital of Philadelphia, Wynnewood, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³The Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Children's Hospital of Philadelphia, Durham, NC
Background/Purpose: Hypogammaglobulinemia following rituximab therapy is a potentially severe complication that can lead to infection-related morbidity and mortality. If recognized, clinicians may prevent infections by…
Abstract Number: 0647 • ACR Convergence 2021
Adherence to Hydroxychloroquine Dosing and Teleretinal Screening: Assessment and Quality Improvement
Brendan Cerk¹, Brian Toy¹, Betty Situ¹, Stavros Savvas² and Leanna Wise³, ¹University of Southern California, Los Angeles, CA, ²Keck School of Medicine of USC, Los Angeles, CA, ³LAC+USC/Keck Medicine of USC, Pasadena, CA
Background/Purpose: Hydroxychloroquine (HCQ) is used in many rheumatologic diseases. The American Academy of Ophthalmology (AAO) put forth guidelines in 2012 regarding retinal screening and dosing…
Abstract Number: 0645 • ACR Convergence 2021
Time Burden of QTc Screening for HCQ Users at a Single VA Rheumatology Clinic
Iziegbe Ehiorobo¹, Anna Montgomery² and Gabriela Schmajuk¹, ¹University of California San Francisco, San Francisco, CA, ²Department of Veterans Affairs, Tiburon, CA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used medication in the treatment of rheumatic diseases. New guidance from the ACR supports routine monitoring of the QT…
Abstract Number: 0649 • ACR Convergence 2021
Optimizing SARS-CoV-2 Vaccine Timing in Rituximab-Treated Patients with Autoimmune Rheumatic Diseases: A Quality Improvement Intervention
Daniel Magliulo¹, Stefanie Wade² and Vasileios Kyttaris³, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³BIDMC, Boston, MA
Background/Purpose: Experience with rituximab (RTX) in autoimmune rheumatic disease (AIRD) has shown a clear association with hypogammaglobulinemia, serious infections, and impaired humoral response to certain…
Abstract Number: 0651 • ACR Convergence 2021
Diagnostic Approach to Identifying Small Fiber Neuropathy in Patients with Sarcoidosis
Bassel Bou Dargham¹, Nima Madanchi², Kelsey Satkowiak¹, Huzaefah Syed¹ and Kelly Gwathmey³, ¹Virginia Commonwealth University Medical Center, RICHMOND, VA, ²Virginia CommonHealth University Medical Center, Richmond, VA, ³Virginia Commonwealth University Health system, Richmond, VA
Background/Purpose: Sarcoidosis is a multisystem granulomatous disease that can affect the nervous system in about 5% of patients. Sarcoidosis associated small fiber neuropathy (SSFN) presents…
Abstract Number: 0650 • ACR Convergence 2021
Use, Procurement Cost, and Adverse Events from IVIg Use in Rheumatic Disease
Francisca Lambert-Fliszar¹, Evelyne Vinet², Sasha Bernatsky¹ and Arielle Mendel³, ¹McGill University, Montréal, QC, Canada, ²McGill University Health Centre, Mont Royal, QC, Canada, ³McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Intravenous immunoglobulin (IVIg) is used in several systemic rheumatic diseases due to postulated immunomodulatory properties. However, IVIg is a scarce and costly resource and…
Abstract Number: 0646 • ACR Convergence 2021
Dark Adaptometry Screening for Hydroxychloroquine Retinopathy: A Pilot Study
Robert Yood¹, Elinor Mody¹, Bradley Daines¹, Kathryn Deliso², Eugenio Candal¹, Ahmed Ramram¹, Stephen Brimer³, Alondra Msallem² and Larry Baitch², ¹Reliant Medical Group, Worcester, MA, ²MCPHS University, Worcester, MA, ³Saint Vincent Hospital, Worcester, MA
Background/Purpose: Hydroxychloroquine (HCQ) is widely used in the treatment of rheumatic diseases. The use of HCQ is complicated by HCQ-induced retinopathy, which may lead to…
Abstract Number: 0640 • ACR Convergence 2021
Implementation of Digital Prompt in Electronic Medical Records Improves Pneumonia Vaccination Rates in Patients Prescribed TNF-Inhibitors
Manjeet Bhamra¹ and Andras Perl², ¹SUNY Upstate Medical University, Syracuse, NY, ²State University of New York, Syracuse, NY
Background/Purpose: Tumor necrosis factor α inhibitors (TNFi) predispose to bacterial infections including pneumonia. In turn, vaccination with pneumococcal 13 valent (PCV13) and pneumococcal 23 valent…
Abstract Number: 0621 • ACR Convergence 2021
Case Series of IgG4-related Disease in African American Patients at Two Large Academic Centers
Jonathan Thaler¹, Sunita Dia² and Florina Constantinescu², ¹MedStar Georgetown University Hospital, Washington, DC, ²Medstar Washington Hospital Center, Washington, DC
Background/Purpose: IgG4-related Disease (IgG4-rD) is a fibroinflammatory disease with highly variable manifestations that can be difficult to diagnose. Response to treatment with prednisone and/or rituximab…
Abstract Number: 0592 • ACR Convergence 2021
Gender Modifies the Effect of Rheumatoid Arthritis on All-Cause Mortality
Srikanta Banerjee¹ and Stephanie Falls², ¹Walden University, Leola, ²PA Department of Health, Leola
Background/Purpose: Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease which predominantly affects joints with varying severity. While RA has been found to be…
Abstract Number: 0529 • ACR Convergence 2021
COPA Syndrome-associated Mutations in Lung Transplant Recipients for Interstitial Lung Disease
Sarah Beshay¹, Isabella Osuna², Jessica Smith¹, Justin Branch³, Laura Muruato³, Marietta DeGuzman³, Pamela McShane¹, Yuelan Ren¹, Rajeev Singh¹, Manuel Silva Carmona³, Sandeep Sahay¹ and Tiphanie Vogel³, ¹Houston Methodist, Houston, ²Rice University, Houston, TX, ³Baylor College of Medicine, Houston, TX
Background/Purpose: COPA syndrome is a rare monogenic cause of immune-mediated lung disease, and it can mimic rheumatic diseases including rheumatoid arthritis (RA) with ILD, lupus…
Abstract Number: 0404 • ACR Convergence 2021
Perifollicular Hypopigmentation in Systemic Sclerosis: Associations with Clinical Features and Internal Organ Involvement
Melody Chung¹, Jamie Perin¹, Carrie Richardson², Christopher Mecoli³, Fred Wigley¹ and Zsuzsanna McMahan⁴, ¹Johns Hopkins University, Baltimore, MD, ²Rush University Medical Center, Chicago, IL, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: Among the autoimmune rheumatic diseases, there is precedent for utilizing cutaneous manifestations of systemic disease as clues to clinical phenotype and disease prognosis. Though…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].